Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APOBEC3A | P31941 | 1/20 | 0.67 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.67 |
| ▸ | PKM | P14618 | 7/20 | 0.63 |
| ▸ | PKLR | P30613 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6224554 | 0.94 | PKM (0.67) | APOBEC3AAPOBEC3GPKMPKLRPOLB | |
| SCHEMBL266849 | 0.94 | PKM (0.67) | APOBEC3AAPOBEC3GPKMPKLRPOLB | |
| SCHEMBL396589 | 0.86 | ALDH1A1 (0.69) | PKMPKLRKMT2ALMNAHTT | |
| SCHEMBL10860773 | 0.86 | PKM (0.77) | PKMPKLRKMT2ALMNAHTT | |
| SCHEMBL264656 | 0.85 | ALDH1A1 (0.67) | PKMPKLRKMT2ALMNAHTT | |
| SCHEMBL3430555 | 0.83 | APOBEC3A (0.67) | APOBEC3AAPOBEC3GPKMRAB9APOLB | |
| SCHEMBL22545826 | 0.82 | APOBEC3A (0.97) | APOBEC3AAPOBEC3GPKMRAB9APOLB | |
| SCHEMBL2856801 | 0.81 | GAA (0.76) | APOBEC3AAPOBEC3GPKMPOLBKMT2A | |
| SCHEMBL22659134 | 0.81 | RAB9A (0.66) | APOBEC3AAPOBEC3GPKMRAB9APOLB | |
| SCHEMBL15746498 | 0.79 | PKM (0.79) | PKMPKLR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1451160-B1 | PYRAZOLE-AMIDES FOR USE IN THE TREATMENT OF PAIN | ICAGEN INC (US) | 2010-01-13 | — | — | EP | claimed |
| EP-1451160-B1 | PYRAZOLE-AMIDES FOR USE IN THE TREATMENT OF PAIN | ICAGEN INC (US) | 2010-01-13 | — | — | EP | disclosed |
| US-20080064690-A1 | PYRAZOLE-AMIDES AND -SULFONAMIDES | ICAGEN, INC. (US) | 2008-03-13 | — | — | US | disclosed |
| US-7223782-B2 | Pyrazole-amides and -sulfonamides | ICAGEN, INC. (US) | 2007-05-29 | — | — | US | disclosed |
| US-20050049237-A1 | Pyrazole-amides and -sulfonamides | ICAGEN, INC. (US) | 2005-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064690-A1 | PYRAZOLE-AMIDES AND -SULFONAMIDES | SCN3A, TRPV3, HCN3 | APOBEC3A 4115/4885APOBEC3G 4521/4885PKM 1321/4885 |
| US-20050049237-A1 | Pyrazole-amides and -sulfonamides | SCN3A, TRPV3, HCN3 | APOBEC3A 4115/4885APOBEC3G 4521/4885PKM 1321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.